ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 254 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 0.72 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $157,537,870 | -19.8% | 5,862,965 | +6.5% | 0.01% | -10.0% |
| Q2 2023 | $196,399,982 | +31.0% | 5,507,571 | -6.7% | 0.01% | +25.0% |
| Q1 2023 | $149,930,307 | -69.0% | 5,902,768 | -50.6% | 0.01% | -42.9% |
| Q4 2022 | $484,314,306 | +178.9% | 11,940,688 | +127.2% | 0.01% | +27.3% |
| Q3 2022 | $173,659,000 | -11.7% | 5,254,432 | -5.9% | 0.01% | -8.3% |
| Q2 2022 | $196,568,000 | -8.7% | 5,582,746 | +19.2% | 0.01% | +9.1% |
| Q1 2022 | $215,323,000 | -16.8% | 4,681,955 | +19.9% | 0.01% | -8.3% |
| Q4 2021 | $258,886,000 | +5.5% | 3,904,771 | -0.7% | 0.01% | -7.7% |
| Q3 2021 | $245,423,000 | -17.4% | 3,931,168 | +9.6% | 0.01% | -18.8% |
| Q2 2021 | $297,020,000 | +20.0% | 3,586,331 | -4.0% | 0.02% | +14.3% |
| Q1 2021 | $247,609,000 | -17.9% | 3,734,120 | -5.0% | 0.01% | -22.2% |
| Q4 2020 | $301,704,000 | +54.2% | 3,932,015 | -13.5% | 0.02% | +38.5% |
| Q3 2020 | $195,627,000 | -7.4% | 4,543,124 | -7.1% | 0.01% | -13.3% |
| Q2 2020 | $211,262,000 | +71.0% | 4,891,447 | +13.9% | 0.02% | +36.4% |
| Q1 2020 | $123,558,000 | -52.8% | 4,294,674 | +4.1% | 0.01% | -38.9% |
| Q4 2019 | $261,615,000 | +90.1% | 4,124,470 | -15.6% | 0.02% | +80.0% |
| Q3 2019 | $137,649,000 | +9.9% | 4,884,636 | +3.3% | 0.01% | +11.1% |
| Q2 2019 | $125,280,000 | +45.1% | 4,727,535 | +0.5% | 0.01% | +28.6% |
| Q1 2019 | $86,329,000 | +37.0% | 4,704,597 | -7.3% | 0.01% | +16.7% |
| Q4 2018 | $63,016,000 | -33.4% | 5,073,775 | +2.8% | 0.01% | -14.3% |
| Q3 2018 | $94,603,000 | +72.5% | 4,934,753 | +22.4% | 0.01% | +40.0% |
| Q2 2018 | $54,832,000 | +197.8% | 4,031,856 | +57.9% | 0.01% | +150.0% |
| Q1 2018 | $18,411,000 | +4368.7% | 2,553,431 | +2186.6% | 0.00% | – |
| Q4 2017 | $412,000 | +68.2% | 111,671 | +97.2% | 0.00% | – |
| Q3 2017 | $245,000 | +129.0% | 56,640 | -15.0% | 0.00% | – |
| Q2 2017 | $107,000 | -94.9% | 66,640 | -94.2% | 0.00% | – |
| Q1 2017 | $2,115,000 | +41.4% | 1,143,666 | +18.5% | 0.00% | – |
| Q4 2016 | $1,496,000 | -85.4% | 965,028 | -30.7% | 0.00% | -100.0% |
| Q3 2016 | $10,233,000 | +100.8% | 1,391,832 | +45.4% | 0.00% | 0.0% |
| Q2 2016 | $5,096,000 | +12.0% | 957,536 | +1.3% | 0.00% | – |
| Q1 2016 | $4,551,000 | – | 944,860 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WESTERN FINANCIAL Corp | 820,264 | $54,392,000 | 33.22% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,260,869 | $216,228,000 | 28.00% |
| L1 Capital Pty Ltd | 296,024 | $19,629,000 | 4.93% |
| Aquilo Capital Management, LLC | 407,926 | $27,050,000 | 4.89% |
| Evolutionary Tree Capital Management, LLC | 72,948 | $4,837,000 | 2.86% |
| ACUTA CAPITAL PARTNERS, LLC | 108,000 | $7,161,000 | 2.58% |
| First Light Asset Management, LLC | 536,836 | $35,598,000 | 2.36% |
| Parkman Healthcare Partners LLC | 70,089 | $4,648,000 | 1.08% |
| Hood River Capital Management LLC | 357,082 | $23,678,000 | 0.76% |
| Vanguard Capital Wealth Advisors | 11,099 | $703,565,000 | 0.60% |